Analyst Price Targets — NKTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 26, 2024 6:47 am | Bill Maughan | Canaccord Genuity | $16.00 | $9.61 | StreetInsider | Nkarta Inc. (NKTX) PT Raised to $16 at Canaccord Genuity |
| March 22, 2024 8:17 am | Gil Blum | Needham | $15.00 | $12.98 | Benzinga | These Analysts Revise Their Forecasts On Nkarta After Q4 Results |
| March 22, 2024 6:35 am | Salim Syed | Mizuho Securities | $25.00 | $8.92 | StreetInsider | Nkarta Inc. (NKTX) PT Lowered to $25 at Mizuho on deprioritization of NKX101 |
| March 22, 2024 3:34 am | Laura Prendergast | Raymond James | $16.00 | $8.92 | StreetInsider | Raymond James Downgrades Nkarta Inc. (NKTX) to Outperform |
| April 26, 2022 4:23 am | — | Raymond James | $32.00 | $18.72 | Benzinga | Raymond James Maintains Outperform on Nkarta, Raises Price Target to $32 |
| April 26, 2022 4:19 am | — | H.C. Wainwright | $36.00 | $18.72 | Benzinga | HC Wainwright & Co. Maintains Buy on Nkarta, Raises Price Target to $36 |
Latest News for NKTX
Nkarta stock jumps after FDA backs protocol changes for ongoing NKX019 studies, enabling outpatient dosing and boosting study efficiency, patient access and commercial potential.
SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on key changes to the ongoing Ntrust-1 and Ntrust-2 clinical trials. The protocol amendments are designed…
SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the 25th Annual Needham Virtual Healthcare Conference.
Nkarta, Inc. (NASDAQ: NKTX - Get Free Report) has earned a consensus rating of "Hold" from the five brokerages that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average
SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today reported financial results for the fourth quarter and year ended December 31, 2025. “2025 was a year of strategic importance for Nkarta as we onboarded a clinical team with deep autoimmune…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NKTX.
U.S. House Trading
No House trades found for NKTX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.